HUE031650T2 - Enteroszolvens készítmény lágy kapszulafal elõállításához - Google Patents

Enteroszolvens készítmény lágy kapszulafal elõállításához Download PDF

Info

Publication number
HUE031650T2
HUE031650T2 HUE14170492A HUE14170492A HUE031650T2 HU E031650 T2 HUE031650 T2 HU E031650T2 HU E14170492 A HUE14170492 A HU E14170492A HU E14170492 A HUE14170492 A HU E14170492A HU E031650 T2 HUE031650 T2 HU E031650T2
Authority
HU
Hungary
Prior art keywords
enteric
soft
acid
gel mass
capsules
Prior art date
Application number
HUE14170492A
Other languages
English (en)
Inventor
Emadeldin M Hassan
Aqeel A Fatmi
Nachiappan Chidambaram
Original Assignee
Banner Life Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banner Life Sciences Llc filed Critical Banner Life Sciences Llc
Publication of HUE031650T2 publication Critical patent/HUE031650T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Claims (8)

  1. EsAeruszotveos készítmény lágy kupazutefal előMlltásátroz Emi*sssia 1 ïiïi Igé o y|M>nf ok L IhHemszolvonslágy kaps/e fahéj. antely gélmassza-készlttnényből van.Lmlukhva, aboi a gélntassza tartalmaz; (s) agy ÍUrnkepzö, vízben oki hard tmlimem an adv zselatin;: (!>) eg y savban oldhatatlan gollmerg amdy egy akrü-rnetakrilsav kopcdirner (e) legalább egy lágyltdszert; és (c) egy vives oldószert; alsói, a savban oldhatatlan polimer lllnakepző polimerhez viszonyított tömegaránya körülbelül 30 %-tóÍ kömibetnl: 4P %4g téried,
  2. 2. Az !, igénypont szerinti enteras zolvens lágy kapsZulahéh Ahol a savban oldhatab· Jatt polimer a gélmassza teljes tömegének körülbelül 3 kk-tdl körülbelül 20 %-ig terjedő hányadát teszi ki,
  3. 3. Az 1, igénypont szómul enieroszolvens lágy kapszrdahék ahol a gêfmassza phl-ja nem haladja meg a 8,5 érteket,
  4. 4. Az I. igénypont szerem etperoszoivens lágy ka pszt hahó:, ahoi az enietxtszolveos lágy kapszuláké)-készítmény nedvességtartalma körülbelül 2 %Adl kőrillheiill 10 %-lg terjed,
  5. 5. Az 1. igénypont szerinti enieroszolvens lágy kapsziüaoég aboi a zselatin kddkeiül 1 uit-tói körülbeiűl 250'ig teríedP Bkmm-száotroal rendelkezik, b, Az L igére pont szerinti emeroszoivom lágy kapszulabek ahol a lags lease; η kővetkezők közül legalább egyet tartalmaz: szosbitók glicerin, ppheüténgiikok citrom-sav, Irieubeitfái vagy ezek ktmibináciői 7. A 6, igénypont szerinti enteroszpi vens lágy kapszidahéj, ahol a lány be szer gnce-rin és trietikeiirât Η, Λa L igénypont own ml ernem osb veer lágy k:gwuknv:fo ahol a vizes oldószer tartalmaz agy lúgos vizes oldatot, amely armrfonlát, rnbruunbedtoxidot, káliom-bidmfodot, eülendlaemu. fodrofolanunt vagy rtieianoiatnint lamdmaa 9. A 8. Igénypont szerlat! ontsroszoiyens lágy kapszuláké), ahol a. lúgos vizes oldószer ammónia,
  6. 10. Eljárás cmerosznh ans lágy kapszula előállítására, amely .eljárás magában foglalja a. következő lépéseket: (a) az I. igénypontban definiált gélmassza előállítása; (p) a gélmassza öntése iümeklfo vagy szalagaidá, Ifoszabály ozott dobok vagy leur letek alkalmazásával; te) enteroszoivens lágy kapszula kialakítása tfcerforgőhengeres eljárással 11. Λ 10. Igénypont szerinti eljárás, adói a filmek vagy szalagok, vastagsága körűd belül 0,381. montöi (0,015 hüvelyk] körülbelül 1,27 nun-ig (05150 hüvelyk) leped.
  7. 12. Az 1, igénypont szerinti en torn szolvens lágy kapszula, ahol a kapszula tartalmaz egy tölteléket, amely folyékony, szilárd vagy a keuö komhmádoju.
  8. 13. Az i. igénypont szerinti enteroszvdvens lágy kapszula, ahol az enteroszolvons lágy kapszula világos vagy átlátszó, de színes.
HUE14170492A 2002-10-01 2003-06-27 Enteroszolvens készítmény lágy kapszulafal elõállításához HUE031650T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41518702P 2002-10-01 2002-10-01

Publications (1)

Publication Number Publication Date
HUE031650T2 true HUE031650T2 (hu) 2017-07-28

Family

ID=32069824

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14170492A HUE031650T2 (hu) 2002-10-01 2003-06-27 Enteroszolvens készítmény lágy kapszulafal elõállításához

Country Status (14)

Country Link
US (2) US8685445B2 (hu)
EP (2) EP1545475B1 (hu)
JP (1) JP5248739B2 (hu)
CN (1) CN1688294A (hu)
AU (1) AU2003299191A1 (hu)
CA (1) CA2500663C (hu)
CY (1) CY1118258T1 (hu)
DK (2) DK1545475T3 (hu)
ES (2) ES2609059T3 (hu)
HU (1) HUE031650T2 (hu)
MX (1) MXPA05003524A (hu)
PT (2) PT2772250T (hu)
SI (2) SI1545475T1 (hu)
WO (1) WO2004030658A1 (hu)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070082046A1 (en) * 2005-10-11 2007-04-12 Banner Pharmacaps, Inc. Enteric valproic acid
JP5406529B2 (ja) 2005-10-26 2014-02-05 バナー ファーマキャプス， インコーポレイテッド カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム
CA2627292C (en) 2005-10-26 2012-04-17 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
US20070148248A1 (en) * 2005-12-22 2007-06-28 Banner Pharmacaps, Inc. Gastric reflux resistant dosage forms
JP5183104B2 (ja) * 2006-06-19 2013-04-17 森下仁丹株式会社 口臭除去用多重ソフトカプセル
GB0706178D0 (en) * 2007-03-29 2007-05-09 Univ Aston Enteric pharmaceutical capsules
WO2009064814A2 (en) 2007-11-12 2009-05-22 Pharmaceutics International, Inc. Tri-molecular complexes and their use in drug delivery systems
EP2223685A4 (en) * 2007-11-13 2013-08-21 Shanghai Huiyuan Vegetal Capsule Co Ltd HARD-GEL CELLULAR, GASTRORESISTANT AND GELATIN-FREE ENVELOPE AND PROCESS FOR PREPARING THE SAME
US8309107B2 (en) 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
CN102307576A (zh) 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
US9011908B2 (en) 2009-04-06 2015-04-21 Banner Life Sciences Llc Progesterone solutions for increased bioavailability
JP2013519686A (ja) * 2010-02-12 2013-05-30 センシエント カラーズ エルエルシー 腸溶性コーティング組成物ならびにその製造法および使用法
JP5890428B2 (ja) * 2010-10-26 2016-03-22 キャプシュゲル・ベルジウム・エヌ・ヴィ バルク腸溶カプセルシェル
EP2844297B1 (en) 2012-05-02 2018-08-15 Capsugel Belgium NV Aqueous dispersions of controlled release polymers and shells and capsules thereof
CN105263462B (zh) * 2013-03-15 2019-11-22 帕西恩软胶公司 无明胶肠溶软胶囊
MX2015014915A (es) * 2013-04-23 2016-03-07 Zx Pharma Llc Composicion multiparticulada con recubrimiento enterico que tiene un subrecubrimiento proteinico.
US9504656B2 (en) 2013-10-21 2016-11-29 Banner Life Sciences, LLC Pharmaceutical compositions for poorly soluble active ingredients
WO2015066176A1 (en) 2013-10-30 2015-05-07 Banner Life Sciences, LLC Enteric soft capsules comprising polyunsaturated fatty acids
EP3065720A1 (en) * 2013-11-04 2016-09-14 Capsugel Belgium NV Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
EP3501510B1 (en) 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10182992B2 (en) 2014-04-07 2019-01-22 Patheon Softgels Inc. Abuse-deterrent controlled release formulations
US10772842B2 (en) 2015-01-09 2020-09-15 Patheon Softgels Inc. Abuse-deterrent opioids
CA2950203C (en) 2014-06-20 2019-09-03 Banner Life Sciences Llc Enteric soft capsule compositions
WO2015200149A1 (en) 2014-06-23 2015-12-30 Banner Life Sciences Llc All natural enteric soft capsules comprising active ingredients
CA2950444C (en) * 2014-06-26 2021-01-12 Banner Life Sciences Llc Enhanced bioavailability of polyunsaturated fatty acids
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
US10471152B2 (en) 2014-08-29 2019-11-12 Capsugel Belgium Nv Colloidal dispersion comprising HPMCAS
SG11201702752RA (en) 2014-10-06 2017-06-29 Fuji Capsule Co Ltd Method of Manufacturing Enteric Seamless Soft Capsule
CA2960631C (en) 2014-10-06 2018-06-05 Fuji Capsule Co., Ltd. Method of manufacturing enteric soft capsule
AU2015328676B2 (en) * 2014-10-08 2017-07-20 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
WO2016161125A1 (en) * 2015-03-31 2016-10-06 University Of Vermont And State Agricultural College Methods for treating cryptosporidiosis using triazolopyridazines
US10182993B2 (en) 2015-04-06 2019-01-22 Patheon Softgels Inc. Compositions for colonic delivery of drugs
JP7296185B2 (ja) 2016-02-04 2023-06-22 シンリックス ファーマ、エルエルシー 重水素化ドンペリドン組成物及び疾患の治療方法
PL239878B1 (pl) 2016-03-30 2022-01-24 Gdanski Univ Medyczny Wodna kompozycja oraz sposób wytwarzania dojelitowych elastycznych filmów do sporządzania kapsułek z wodnej kompozycji oraz dojelitowy elastyczny film do sporządzania kapsułek miękkich
NL2017219B1 (en) * 2016-07-22 2018-01-30 Rousselot B V Low cross-linking gelatine
BR112019016091A2 (pt) 2017-03-08 2020-04-14 Cinrx Pharma Llc formulações farmacêuticas de floroglucinol e trimetilfloroglucinol
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
SG11202008715WA (en) 2018-03-15 2020-10-29 R P Scherer Technologies Llc Enteric softgel capsules
CN108619523B (zh) * 2018-03-23 2020-06-30 浙江工业大学 一种可用于快速热塑包衣制剂的包衣膜片及其制备方法
WO2020144591A2 (en) * 2019-01-09 2020-07-16 Antony Benny Preparation of purified withanoside x from withania somnifera plant materials and its medicinal use for the treatment of health disorders
CN109566829A (zh) * 2019-02-11 2019-04-05 广东国方医药科技有限公司 牡丹籽油肠溶凝胶糖果及其制备方法
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
CN113747882A (zh) 2019-05-07 2021-12-03 博士医疗爱尔兰有限公司 甲基纳曲酮的液体口服剂量制剂
WO2021011177A1 (en) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Enteric proton pump inhibitor softgel capsule
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
EP4142727A1 (en) 2020-05-02 2023-03-08 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
CA3119012C (en) * 2021-05-18 2023-10-17 Gelentroceutics Inc. Formulation of intrinsically acid-resistant vegetarian-based and gelatin-based soft gel capsules for pharmaceutical/nutraceutical products
WO2023250297A1 (en) 2022-06-21 2023-12-28 Nutrition & Biosciences Usa 1, Llc Film forming delayed/enteric formulations for hard shell capsules, films and coatings

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826666A (en) * 1972-07-20 1974-07-30 Parke Davis & Co Enteric capsules
DE2340060A1 (de) * 1973-08-08 1975-02-20 Scherer Gmbh R P Magensaftresistente gelatinekapseln und verfahren zu deren herstellung
US4138013A (en) * 1976-08-27 1979-02-06 Parke, Davis & Company Enteric capsules
GR78492B (hu) 1982-03-26 1984-09-27 Warner Lambert Co
US4790881A (en) * 1982-03-26 1988-12-13 Warner-Lambert Company Molded hydrophilic polymer
DE3222476A1 (de) 1982-06-15 1983-12-15 Warner-Lambert Co., 07950 Morris Plains, N.J. Magensaftresistente weichgelatinekapseln und verfahren zu ihrer herstellung
US4518433A (en) 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4500453A (en) * 1984-06-29 1985-02-19 Dynagel Incorporated Cross-linked protein composition using aluminum salts of acetic acid
US4816259A (en) * 1987-02-12 1989-03-28 Chase Chemical Company, L.P. Process for coating gelatin capsules
US5194464A (en) * 1988-09-27 1993-03-16 Takeda Chemical Industries, Ltd. Enteric film and preparatoin thereof
US6482516B1 (en) 1993-07-20 2002-11-19 Banner Pharmacaps, Inc. Enrobed tablet
US5146730A (en) 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
US5330759A (en) 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
KR20010012402A (ko) * 1997-05-09 2001-02-15 세이지 파마슈티칼스, 인크. 안정한 약제학적 경구 투여형
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6193999B1 (en) * 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
DE19922537A1 (de) * 1999-05-10 2000-11-16 Roland Bodmeier Darreichungsform zur Applikation in Körperöffnungen
DE60016617T2 (de) * 1999-10-01 2005-04-28 Natco Pharma Ltd., Banjara Hills Magensaftresistente gelartige weichkapsel
EP1184033A1 (en) * 2000-09-01 2002-03-06 Warner-Lambert Company Pectin film compositions
WO2004012701A2 (en) * 2002-08-02 2004-02-12 Scitech Centre NOVEL pH DEPENDENT ROBUST ENTERIC POLYMERIC CONTAINER, AN IMPROVEMENT OVER EXISTING ENTERIC DOSAGE FORMS.

Also Published As

Publication number Publication date
DK2772250T3 (en) 2016-12-05
JP5248739B2 (ja) 2013-07-31
EP2772250B1 (en) 2016-09-28
ES2500316T3 (es) 2014-09-30
US20140348879A1 (en) 2014-11-27
ES2609059T3 (es) 2017-04-18
CY1118258T1 (el) 2017-06-28
JP2006505542A (ja) 2006-02-16
DK1545475T3 (da) 2014-07-28
CA2500663C (en) 2013-05-28
MXPA05003524A (es) 2005-10-04
SI2772250T1 (sl) 2017-03-31
WO2004030658A1 (en) 2004-04-15
CA2500663A1 (en) 2004-04-15
US9433585B2 (en) 2016-09-06
US8685445B2 (en) 2014-04-01
SI1545475T1 (sl) 2014-10-30
US20060165778A1 (en) 2006-07-27
CN1688294A (zh) 2005-10-26
PT1545475E (pt) 2014-09-16
EP1545475B1 (en) 2014-07-16
EP2772250A1 (en) 2014-09-03
EP1545475A1 (en) 2005-06-29
PT2772250T (pt) 2017-01-02
AU2003299191A1 (en) 2004-04-23

Similar Documents

Publication Publication Date Title
CA2500663C (en) Enteric composition for the manufacture of soft capsule wall
DE69918703T2 (de) Filmbildende zusammensetzungen aus modifizierter stärke
US4140756A (en) Film-coated matrix core tablet
DE69825592T2 (de) Filmbeschichtungen und filmbeschichtungszusammensetzungen auf der basis von dextrin
TWI793141B (zh) 腸溶性硬質膠囊
EP1729742A1 (en) Enteric coatings for orally ingestible substrates
DE60127674T2 (de) Verwendung einer acetylierten vorgelatinierten stärke mit einem hohen gehalt von amylose
EP3205339B1 (en) Method of manufacturing enteric seamless soft capsule
RU2563133C2 (ru) Пленкообразующая композиция для нанесения покрытий на основе твердых порошкообразных соединений
JP5489471B2 (ja) Ｐｅｇ充填硬質カプセル剤のバンドシール
US9254270B2 (en) Enteric soft capsules
US20070048366A1 (en) Gelatin-based coatings having improved durability
TW201909888A (zh) 包衣組成物、包衣膜、包衣製劑及其製造方法
US20130209554A1 (en) Novel gelatin capsule compositions and methods of making
JP2022123274A (ja) 腸溶性硬質カプセル
WO2013006470A1 (en) Novel gelatin capsule compositions and methods of making
JP7366893B2 (ja) 腸溶性硬質カプセル
EP2306987B1 (de) Verfahren zum beschichten von tabletten
JP2021070663A (ja) コーティング組成物、被覆固形製剤、被覆固形製剤の製造方法、コーティング方法
WO2009023029A1 (en) Gelatin-based coatings having improved durability